Quantitative PET Imaging Using (18)F Sodium Fluoride in the Assessment of Metabolic Bone Diseases and the Monitoring of Their Response to Therapy

Glen M Blake; Musib Siddique; Michelle L Frost; Amelia E B Moore; Ignac Fogelman

doi:10.1016/j.cpet.2012.04.001

Quantitative PET Imaging Using (18)F Sodium Fluoride in the Assessment of Metabolic Bone Diseases and the Monitoring of Their Response to Therapy

PET Clin. 2012 Jul;7(3):275-91. doi: 10.1016/j.cpet.2012.04.001. Epub 2012 May 31.

Authors

Glen M Blake¹, Musib Siddique¹, Michelle L Frost¹, Amelia E B Moore¹, Ignac Fogelman²

Affiliations

¹ Osteoporosis Unit, King's College London, King's Health Partners, Guy's Hospital, London SE1 9RT, UK.
² Department of Nuclear Medicine, King's College London, King's Health Partners, Guy's Hospital, London SE1 9RT, UK.

PMID: 27157458
DOI: 10.1016/j.cpet.2012.04.001

Abstract

Studies of bone remodeling using bone biopsy and biochemical markers of bone turnover measured in serum and urine are important for investigating how new treatments for osteoporosis affect bone metabolism. Positron emission tomography with (18)F sodium fluoride ((18)F NaF PET) for studying bone metabolism complements these conventional methods. Unlike biochemical markers, which measure the integrated response to treatment across the whole skeleton, (18)F NaF PET can distinguish changes occurring at sites of clinically important osteoporotic fractures. Future studies using (18)F NaF PET may illuminate current clinical problems, such as the possible association between long-term treatment with bisphosphonates and atypical fractures of the femur.